A Multicentric, Open-label, Non-randomized Study to Evaluate the Pharmacokinetic, Safety and Tolerability of ITF2357 Given as an Oral Single 50 mg Dose in Participants With Chronic Hepatic Impairment Relative to Matched Participants With Normal Hepatic Function

Italfarmaco4 个研究点分布在 2 个国家目标入组 24 人开始时间: 2025年5月29日最近更新: 2026年6月18日

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 24
试验地点: 4
主要终点: Maximum plasma concentration observed (Cmax) of ITF2357

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

详细描述

This study evaluated the effect of mild and moderate hepatic impairment (HI) on the pharmacokinetics of ITF2357 and its metabolites, along with the safety and tolerability in this patient population.

The total number of participants enrolled in the study was 24 subjects:

8 participants with mild HI (Child-Pugh class A)
8 participants with moderate HI (Child-Pugh class B)
8 participants with normal hepatic function (control group)

Each participant went through:

A screening period from Day (D)-28 to D-2
One 6-day/5-night inpatient period (from D-1 evening to D5 morning)
An end-of-study evaluation to be done on D10 (±1 day).

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Basic Science
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•for Participants with HI:
•Male or female participants, between 18 and 75 years of age, inclusive.
•Body weight between 60.0 and 110.0 kg, inclusive if male, and between 50.0 and 100.0 kg, inclusive if female, body mass index (BMI) between 18.00 and 34.99 kg/m2, inclusive.
•Stable chronic liver disease assessed by medical history, physical examination, laboratory values.
•Vital signs after 10 minutes resting in supine position within the following range [or if out of range, considered not clinically significant (NCS) by the Investigator]: 95 mmHg < systolic blood pressure (SBP) < 180 mmHg; 45 mmHg < diastolic blood pressure (DBP) < 100 mmHg; 40 bpm < heart rate (HR) < 100 bpm.
•12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances were participants enrolled with corrected QT according to Fridericia (QTcF) > 450 ms.
•Any confirmed clinically relevant abnormal laboratory test that, on Investigator's judgment, was inconsistent with the subject's status as a patient with hepatic impairment. However, renal function assessed using the estimated glomerular filtration rate (eGFR) calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula had to be strictly above 60 mL/min/1.73m².
•Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.
•Female participants of non-childbearing potential, defined as one of the following:
•At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and follicle-stimulating hormone (FSH) in the range for menopausal female confirmed by blood test according to current local standards at screening;
•Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.
•Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to Clinical Trials Coordination Group [CTCG] recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:
•combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
•progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
•intrauterine device (IUD);
•intrauterine hormone-releasing system (IUS);
•bilateral tubal occlusion;
•vasectomized partner;
•sexual abstinence (when in line with the preferred and usual subject's lifestyle).
•Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception.
•Had given written informed consent prior to any procedure related to the study.
•Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
•Not under any administrative or legal supervision.
•For moderate HI cohort: Child-Pugh total score ranging from 7 to 9, inclusive.
•For mild HI cohort: Child-Pugh total score ranging from 5 to 6, inclusive.
•Male participants had to agree not to donate sperm from inclusion up to 3 months after ITF2357 dosing.

排除标准

•for Participants with HI:
•Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecological (if female), or infectious disease, or signs of acute illness.
•Hepatocarcinoma.
•Acute hepatitis.
•Hepatic encephalopathy grade 2, 3, and
•Blood donation within 2 months before inclusion.
•Symptomatic postural hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥ 30 mmHg within 3 minutes when changed from supine to standing position.
•Presence or history of drug hypersensitivity, or allergic disease, except seasonal rhinitis, diagnosed and treated by a physician.
•History or presence of regular use of recreational drugs or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis) within 2 years before inclusion.
•Smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking over 5 cigarettes per day from D-1 and throughout the entire institutionalization (i.e. up to D5).
•Excessive consumption of beverages with xanthine bases (more than 4 cups or glasses per day).
•If female, pregnancy [defined as positive β-human choriogonadotropin (β-HCG) blood test] or breast feeding.
•Any significant change in chronic treatment medication within 14 days before inclusion.
•Consumption of PgP or BCRP potent inducers or inhibitors that could impact the PK of the investigational product within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication before inclusion.
•Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the EOS visit is completed.
•Any vaccination, including COVID-19 within 2 weeks before inclusion.
•Any participant who, in the judgment of the Investigator, was likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
•Any participant in the exclusion period of a previous study according to applicable regulations.
•Any participant who could not be contacted.
•Any participant who was the Investigator or any co-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
•Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
•Positive results on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates) unless this result was secondary to a documented medical prescription (only for benzodiazepines and cannabinoids).
•Positive alcohol breath test.
•Any consumption of citrus fruits (grapefruit, Seville orange, etc.) or their juices within 5 days before inclusion.
•Medications that prolong the QTc interval (refer to the list provided in Section 12 of Appendix 16.1.1) within 14 days before inclusion or within 7 times the elimination half-life before inclusion.
•Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the last ECG at EOS is completed.
•Had a risk factor of QT prolongation (as for example electrolyte imbalances) or a personal or a family history of prolonged QT interval syndrome or torsade de pointes, or family history of sudden death.
•Inclusion Criteria for Participants with normal hepatic function:
•Male or female participants, between 18 and 75 years of age, inclusive.
•Body weight within 10% of the mean body weight of the participants with moderate HI, and BMI between 18.00 and 34.99 kg/m2, inclusive.
•Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
•Vital signs after 10 minutes resting in the supine position within the following range (or if out of range, considered NCS by the Investigator): 95 mmHg < SBP < 140 mmHg; 45 mmHg < DBP < 90 mmHg; 40 bpm < HR < 100 bpm.
•12-lead ECG without clinically significant abnormality, in the judgment of the Investigator; in no circumstances participants could have been enrolled with QTcF > 450 ms.
•Laboratory parameters within the normal range, unless the Investigator considered an abnormality to be clinically irrelevant for healthy participants, except in the case of platelets, white blood cells and hemoglobin below lower limit of normal (LLN). However serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase), total bilirubin (unless the participant has documented Gilbert's syndrome, with a maximum bilirubin level lower than 3 x upper limit of normal (ULN), and any parameter for which there was an explicit stopping rule could not exceed the upper laboratory range; renal function assessed using the eGFR calculated by the 2021 CKD-EPI formula had to be strictly above 60 mL/min/1.73m².
•Female participants who were not pregnant or nursing at screening and D-1, or who were not planning to become pregnant during study period and until 90 days after the IMP administration.
•Female participants of non-childbearing potential, defined as one of the following:
•At least 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age) and FSH in the range for menopausal female confirmed by blood test according to current local standards at screening.
•Those with history of hysterectomy or surgical removal of both ovaries or bilateral tubal ligation performed at least 90 days prior to screening.
•Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to CTCG recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:
•combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation oral, intravaginal or transdermal;
•progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable;
•intrauterine device (IUD);
•intrauterine hormone-releasing system (IUS);
•bilateral tubal occlusion;
•vasectomized partner;
•sexual abstinence (when in line with the preferred and usual subject's lifestyle).
•Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM were not acceptable methods of contraception.
•Had given written informed consent prior to any procedure related to the study.
•Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
•Not under any administrative or legal supervision.
另有 22 项未显示

研究组 & 干预措施

Healthy Volunteers

Experimental

Participants with normal hepatic function (control group)

干预措施: ITF2357 (Drug)

Moderate HI

Experimental

Patients with moderate HI (Child-Pugh class B)

干预措施: ITF2357 (Drug)

Mild HI

Experimental

Patients with mild HI (Child-Pugh class A)

干预措施: ITF2357 (Drug)